Drug Development Pipeline
Liprotamase (Sollpura) is a pancreatic enzyme replacement that is not prepared from animal sources.
Multiple phase 3 studies to look at the safety and effectiveness of liprotamase in people with CF ages 7 years and older have been completed.
A phase 3 study to look at the safety and effectiveness of a water-soluble formulation of liprotamase did not meet its primary endpoint. No further development is planned at this time.
This program is sponsored by Anthera Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. It is being conducted within the Therapeutics Development Network.
Recent Liprotamase Studies
Completed with Results
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More